Brookfield wants to revive a South Carolina megaproject failure known as ‘Nukegate.’ Can it succeed where others failed?

Brookfield agreed to buy a 75% stake in the unfinished V.C. Summer nuclear units for US$2.7 billion and will spend 18-24 months assessing whether to proceed, with completion potentially taking another 5-7 years and costing up to US$200 million to evaluate. The article highlights major execution, regulatory, financing and partner-risk issues after Westinghouse’s earlier collapse at the site, while noting that roughly 85% of required components are already on hand. The deal could benefit Westinghouse, Brookfield, Santee Cooper and the broader U.S. nuclear buildout, but the outcome remains highly uncertain.

Analysis

BAM is being paid to underwrite a political option, not a pure project-finance deal. The real value is that Brookfield can turn an orphaned, partially de-risked asset into a template for follow-on AP1000 deployments, while keeping the much larger upside in services, licensing, and capital-light structuring. If the restart works, the market is likely underestimating the duration of the earnings tail: the first economics accrue over years, but the re-rating can happen earlier if Brookfield proves it can package risk in a way utilities can stomach.

The second-order winner may be Cameco, because any credible Westinghouse revival increases the value of the installed base and the recurring-service stream more reliably than new-build sales do. KEP looks like the most fragile beneficiary: if Washington keeps courting alternatives, the market is signaling that Westinghouse may not be the sole policy favorite, which compresses the expected monopoly premium on AP1000 deployment. That said, the real competitive moat is not the reactor design itself but the ability to finance, insure, and execute—areas where Brookfield is more credible than legacy nuclear contractors.

The key risk is time. This is a 18–24 month feasibility and permitting story before it becomes a construction story, and then a 5–7 year completion story if all goes well; any headline-driven rerating can reverse quickly if the administration loses patience or if the NRC process becomes less accommodating than expected. The market is probably underpricing two failure modes: hidden requalification costs on long-idled components, and partner-level dilution if Brookfield has to bring in a utility/off-taker on unfavorable terms.

Consensus seems too focused on the binary of 'nuclear revival' versus 'nuclear failure.' The more important question is whether Brookfield can make the project equity-like for downstream buyers while keeping its own downside limited. If it can, the trade is less about one plant and more about the resurrection of a repeatable, government-supported capital stack for large baseload assets in the U.S.

Key Decisions for Investors

• Long BAM on any pullback over the next 2-6 weeks: asymmetric exposure to a policy-backed option with multiple monetization paths; stop if Brookfield signals it will take principal construction risk rather than structuring risk.
• Add CM as a medium-term beneficiary of higher Westinghouse utilization and service backlog; prefer a staggered entry over 1-3 months since the rerating should lag BAM but be more durable if execution holds.
• Avoid chasing KEP strength; treat any rally as a chance to fade or hedge, because policy optionality is being repriced toward U.S.-aligned counterparts and the market may be overestimating its participation in the next wave.
• Pair trade: long BAM / short a basket of utility developers with weak balance sheets and nuclear ambitions over 3-6 months; Brookfield’s edge is structuring, while capital-constrained peers face financing risk and execution slippage.
• Use call spreads on BAM rather than outright equity if you expect a headline-driven move within 6-9 months; the thesis is a low-probability, high-upside catalyst with meaningful downside if feasibility findings disappoint.